ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Asset Turnover : 0.00 (As of Dec. 2023)

ImmuneOnco Biopharmaceuticals (Shanghai) Asset Turnover Chart

Competitive Comparison of ImmuneOnco Biopharmaceuticals (Shanghai)'s Asset Turnover

For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuneOnco Biopharmaceuticals (Shanghai)'s Asset Turnover distribution charts can be found below:

* The bar in red indicates where ImmuneOnco Biopharmaceuticals (Shanghai)'s Asset Turnover falls into.

ImmuneOnco Biopharmaceuticals (Shanghai) Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

ImmuneOnco Biopharmaceuticals (Shanghai)'s Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

ImmuneOnco Biopharmaceuticals (Shanghai)  (HKSE:01541) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

ImmuneOnco Biopharmaceuticals (Shanghai)'s annulized ROE % for the quarter that ended in Dec. 2023 is

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

^** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

ImmuneOnco Biopharmaceuticals (Shanghai)'s annulized ROA % for the quarter that ended in Dec. 2023 is

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.

ImmuneOnco Biopharmaceuticals (Shanghai) Asset Turnover Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Business Description